Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches

SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim is the latest global top 20 biopharma company to commit to moving to Veeva Vault CRM.

"We are excited to bring our innovative research to patients around the world with up to 25 new treatment launches by 2030. Veeva has been our global CRM standard for many years, and we are eager to build on our successful partnership and help shape the future of life sciences with a commitment to move to Veeva Vault CRM," said Uday Bose, head of human pharma global customer experience excellence and business steering at Boehringer Ingelheim. "Our goal to deliver outstanding customer experiences is shared with Veeva and our continued collaboration promises to help transform commercial operations to accelerate launch processes and drive highly personalized engagement."

Boehringer Ingelheim is seeking to expand on its existing Veeva Commercial Cloud solutions and its One Medicine and Amplify platforms, which connect development processes and data on Veeva Development Cloud.

"Boehringer Ingelheim has a forward-looking approach to unifying its technology and data landscape to rapidly deliver therapies that improve human and animal health," said Tom Schwenger, president and chief customer officer at Veeva. "I am thrilled to see our long-standing partnership expand with their move to Veeva Vault CRM."

Boehringer Ingelheim will join the opening keynote at Veeva Commercial Summit Europe, sharing how Vault CRM is a key enabler of future commercial agility, innovation, and differentiation.

Additional Information

For more on Veeva Vault CRM, visit: veeva.com/VaultCRM

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.